China Resources Pharmaceutical Group Ltd operates within the Drugs, proprietaries, and sundries sector.
In addition to historical fundamental analyses, the complete report available to purchase compares China Resources Pharmaceutical Group Ltd with three other
drug stores in Asia:
Shanghai Pharmaceuticals Holding Co Ltd
sales of 191.91 billion Chinese Renmimbi [US$29.96 billion]
of which 85%
was Pharmaceutical Merchant Wholesale),
Medipal Holdings Corporation
(3.25 trillion Japanese Yen [US$29.54 billion]
of which 66%
was Pharmaceuticals And Food Precessing Whol), and
Alfresa Holdings Corporation
based in JAPAN
(2.70 trillion Japanese Yen [US$24.50 billion]
of which 87%
was Wholesale Business of Pharmaceuticals fo).
During the year ended December of 2020, sales at
China Resources Pharmaceutical Group Ltd were HK$200.42 billion (US$25.82 billion).
decrease of 2.0%
versus 2019, when the company's sales were HK$204.45 billion.
Contributing to the drop in overall sales was the 4.6% decline
in Manufacturing Segment, from HK$30.69 billion to HK$29.29 billion.
There were also decreases in sales in
Distribution Segment (down 1.6% to HK$164.44 billion)
However, these declines were partially offset by the increase in sales of
Retail Segment (up 0.1% to HK$6.47 billion)
Others (up 10.4% to HK$225.99 million)